Clinical Trials Directory

Trials / Completed

CompletedNCT03350451

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Alnylam Pharmaceuticals · Industry
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in participants with Primary Hyperoxaluria Type 1.

Conditions

Interventions

TypeNameDescription
DRUGLumasiranMultiple doses of lumasiran by SC injection

Timeline

Start date
2018-04-04
Primary completion
2023-02-07
Completion
2023-02-07
First posted
2017-11-22
Last updated
2024-04-25
Results posted
2024-04-25

Locations

9 sites across 5 countries: France, Germany, Israel, Netherlands, United Kingdom

Regulatory

Source: ClinicalTrials.gov record NCT03350451. Inclusion in this directory is not an endorsement.

An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 (NCT03350451) · Clinical Trials Directory